Fertility & IVF

Requires Standards 1–7 verified first

5 criteria

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.

REFERENCES

1. [65] Alpha Scientists in Reproductive Medicine, ESHRE Special Interest Group of Embryology. The Istanbul consensus update: a revised ESHRE/ALPHA consensus on oocyte and embryo static and dynamic morphological assessment. Hum Reprod. 2025 — establishes internationally recognised, evidence-based criteria for oocyte and embryo assessment.

Embryo development is genuinely sensitive to laboratory conditions, and a subtle, undetected drift in temperature or air quality can affect outcomes without any visible sign until results are reviewed much later — regular, defined quality control is what catches this before it affects patients.

1 Temperature is monitored consistently but air quality checks are less regular.

Each laboratory condition can independently affect embryo development.

2 Quality control happens but results aren't reviewed by someone with authority to act on them.

Monitoring without genuine review provides limited real protection.

3 The assessment standard is followed for routine cases but applied less consistently for complex ones.

Complex cases carry at least the same real stakes as routine ones.

Week 1 Review current assessment practice against the recognised international standard.

Week 2 Establish or verify a defined, regular laboratory quality control schedule.

Week 3 Define a specific response protocol for out-of-range conditions.

Ongoing Review quality control logs and assessment consistency periodically.

Ask for actual quality control logs, not a general assurance conditions are stable.

Dated, specific records are the only real evidence of consistent verification.

Ask two different embryologists to assess the same case criteria.

Consistent answers reveal genuine standardisation; differing answers reveal informal, individual practice.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.

REFERENCES

1. [66] European Society of Human Reproduction and Embryology. ESHRE guideline: ovarian stimulation for IVF/ICSI — an update. Hum Reprod. 2025 — establishes individualised, response-based protocol adjustment as core to safe ovarian stimulation practice.

Ovarian stimulation carries real, serious risk — including ovarian hyperstimulation syndrome — that genuinely depends on individual patient response, and a protocol that doesn't adjust to that response isn't providing the protection real physician oversight is meant to offer.

1 Initial protocol determination is individualised but adjustments during stimulation become more standardised.

Ongoing responsiveness to monitoring matters as much as the initial individualised decision.

2 Monitoring happens but isn't consistently reviewed by the physician in time to adjust the protocol meaningfully.

Delayed review limits the ability to actually respond to what monitoring reveals.

3 OHSS risk is recognised for high-risk patients but the process isn't consistently applied to lower apparent risk.

Risk assessment itself can be wrong; a consistent process protects against that possibility.

Week 1 Review a sample of stimulation protocols for genuine individual determination.

Week 2 Establish a consistent process for adjusting protocols based on real-time monitoring.

Week 3 Define and brief staff on a specific OHSS recognition and management process.

Ongoing Audit protocol individualisation and OHSS management readiness periodically.

Compare two different patients' protocols and documented reasoning.

Genuinely different content reveals real individualisation; near-identical protocols reveal standardisation.

Ask the physician to describe a specific OHSS case, real or hypothetical, in detail.

Specific, detailed knowledge reveals genuine readiness rather than general awareness.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Requires improvement plan.

REFERENCES

1. [67] Single embryo transfer, with explicit discussion of multiple-pregnancy risk as part of the transfer decision, is established international guidance for reducing avoidable multiple-pregnancy risk in IVF, distinct from general transfer procedure consent.

Multiple pregnancy carries real, elevated risk to both the pregnant patient and the babies, and this is a risk patients can genuinely weigh and choose about — but only if the conversation actually happens specifically, not folded into general transfer consent.

1 The discussion happens for patients considering multiple-embryo transfer but not those already planning single transfer.

Even a patient inclined toward single transfer benefits from understanding why the choice matters.

2 Risk is mentioned but single embryo transfer isn't genuinely presented as an equally valid option.

A mentioned risk without a genuine alternative doesn't provide a real choice.

3 The conversation happens once, early in treatment, and isn't revisited at the actual point of transfer decision.

Circumstances and patient thinking can genuinely change by the time transfer is actually being decided.

Week 1 Review current pre-transfer consent practice for specific multiple-pregnancy risk discussion.

Week 2 Build a specific discussion point into the pre-transfer consultation, distinct from general consent.

Week 3 Train staff to genuinely present single embryo transfer as a real option.

Ongoing Spot-check patient understanding after pre-transfer consultations.

Ask the patient, not the clinician, to describe the risk discussion they had.

This tests actual understanding, not staff confidence in their own explanation.

Ask specifically whether single embryo transfer was presented as a genuine option.

A direct question often reveals what a general consent review won't.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Requires improvement plan.

REFERENCES

1. [68] Realistic, individualised success rate discussion, distinct from generic clinic-wide statistics, is identified as an essential component of genuinely informed consent in fertility treatment, given the significant emotional and financial stakes involved.

Fertility treatment carries a weight most medical consent doesn't — genuine emotional investment and real financial cost, often across multiple attempted cycles — and a consent process that addresses only the physical procedure while treating success as assumed doesn't reflect what the patient is actually deciding.

1 Individualised success rates are discussed for the first cycle but not revisited for subsequent attempts.

Each cycle's own realistic likelihood deserves its own honest discussion.

2 Financial discussion covers the immediate cycle cost but not the realistic possibility of needing further cycles.

Genuine financial transparency includes the realistic full picture, not only the immediate cost.

3 The conversation is thorough at initial consultation but not revisited as treatment progresses.

Understanding and circumstances can genuinely change over the course of treatment.

Week 1 Review current consent practice for individualised, not generic, success rate discussion.

Week 2 Build individualised success rate and unsuccessful-cycle discussion into the consent process.

Week 3 Establish upfront financial discussion covering realistic multiple-cycle possibility.

Ongoing Spot-check patient understanding of both clinical and financial realities.

Ask a patient what success rate they were told, and compare it to this patient's actual individual profile.

This reveals whether figures given were genuinely individualised or generic.

Ask whether the possibility of needing more than one cycle was discussed before treatment began.

This is where financial transparency most commonly falls short in practice.

ALL YES Standard likely met. ANY PARTIAL Improvement plan required. ANY NO Blocks accreditation until resolved.

REFERENCES

1. [69] Human Fertilisation and Embryology Authority. Code of Practice. 9th ed. London: HFEA; 2021 — mandates witnessing, either double manual witnessing by a second qualified individual or a certified electronic witnessing system, at every critical step of gamete and embryo handling.

A gamete or embryo mix-up is among the most serious possible errors in any medical setting, and while genuinely rare, it is real and documented — a defined, verified witnessing protocol at every critical step is what makes this risk structurally difficult, not just hoped against.

1 Witnessing is rigorous for embryo transfer but less consistently applied to earlier steps like insemination.

Every critical step carries the same real mix-up risk, not transfer alone.

2 An electronic witnessing system exists but isn't used consistently for every applicable step.

A system that exists but isn't consistently used doesn't provide the intended protection.

3 Witnessing happens but records don't specify exactly which steps were witnessed by whom.

Traceability requires specific, retained detail, not a general confirmation witnessing occurred.

Week 1 Map every critical gamete and embryo handling step against current witnessing coverage.

Week 2 Close any gap in witnessing coverage for critical steps.

Week 3 Establish specific, retained traceability records for every witnessed step.

Ongoing Audit witnessing consistency and traceability records periodically.

Ask to see the traceability record for a specific, recent case.

A specific, real record is the only genuine evidence witnessing actually happened as described.

Observe a witnessed step directly if timing allows.

Genuine independence between operator and witness is best confirmed through direct observation.